Investigator Perspectives

Sarat Chandarlapaty, MD, discusses the treatment landscape of metastatic ER+/HER2- breast cancer, including observations made from the results of the AMEERA-1 trial and the use of amcenestrant as a therapy option.

Evan Y. Yu, MD, reviews the use of LuPSMA radioligand therapy and the role of precision medicine in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Expert reflections on the optimal identification and management of unresectable hepatocellular carcinoma given recent updates from the IMbrave150 trial.

In this Investigator Perspectives, Yi-Bin Chen, MD discusses the difference between acute and chronic graft versus host disease, the initial therapeutic management of these diseases, and the newly-approved agents for steroid-refractory disease. He also provides his insights regarding future directions and unmet needs for steroid-refractory GVHD.

An expert in hematology-oncology provides key insights into treatment considerations for patients with hepatocellular carcinoma and reviews safety and efficacy data from the phase 3 REFLECT Trial of lenvatinib for patients with unresectable disease.

Andrew J. Armstrong, MD, MSc, evaluates the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Robert J. Motzer, MD, gives a comprehensive background and analysis on the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus versus sunitinib in the treatment of advanced renal cell carcinoma.

Sara Hurvitz, MD, reviews the implications of the AMEERA-5 trial, a randomized, double-blind phase III study of amcenestrant + palbociclib vs letrozole + palbociclib in the treatment of ER+/HER2- advanced breast cancer.

Lori Wirth, MD provides an overview of differentiated thyroid cancer and reviews key data from the SELECT trial examining the use of lenvatinib.

Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.

Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).

Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.

Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.

David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, reacts to the growing interest around identifying NTRK gene fusions in various solid tumor types and treating appropriate patients with oral TRK inhibitors.

Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.

Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.

Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.

Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.

Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.

The most interesting developments and approvals in breast cancer treatment in the last year and expectations regarding data that will be presented on at the upcoming 2020 San Antonio Breast Cancer Symposium.

Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.

A key opinion leader provides insight into recent data updates from ongoing trials studying the management of GvHD with promising regimens. 

A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.

Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.

A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.

A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.

Saeed Sadeghi, MD, comments on the utilization of FGFR2 inhibitors as treatment for advanced cholangiocarcinoma.

A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).

A discussion on the development of targeted therapies for the management of advanced cholangiocarcinoma, with consideration of multiple ongoing trials with notable outcomes.

How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.